BALPHARMA2024-01-012024-03-31 BALPHARMA2024-01-012024-03-31 BALPHARMA2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member BALPHARMA2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member BALPHARMA2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524824 BALPHARMA NOTLISTED Bal Pharma Limited Equity 2023-04-01 2024-03-31 2024-05-28 2024-04-30 INR Lakhs Yearly 16:30:00 17:45:00 2024-05-28 2024-05-28 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceuticals 2024-01-01 2024-03-31 Audited Standalone 945796000.00 22344000.00 968140000.00 518948000.00 47612000.00 -28856000.00 145574000.00 41179000.00 17628000.00 159361000.00 901446000.00 66694000.00 0.00 66694000.00 10213000.00 -5705000.00 4508000.00 0.00 62186000.00 0.00 0.00 0.00 0.00 62186000.00 3537000.00 65723000.00 0.00 0.00 158043000.00 10 4.16 4.18 0.00 0.00 4.16 4.18 1. The above audited standalone financial results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th May 2024. 2. The standalone financial results has been prepared in accordance with Companies ( Indian Accounting Standards) Rules, 2015 ( IND AS ), prescribed under section 133 of Companies Act, 2013. 3. The Company has only one reportable segment namely Pharmaceuticals . 4. The Company has a outstanding recoverability of Rs. 86989 Lakhs and Rs. 152.23 Lakhs from its subsidiaries Lifezen Healthcare Private Limited and Balance Clinics LLP. The said subsidiaries have incurred losses and have a negatived networth. However the management is confident that with infusion of additional funds, introduction of new brands and renewed marketing, internal restructring, the Companies can be reviews and the amounts recovered. 5. The Group has not received any intimation or information with regard to its vendors registration as a Micro, Small and Medium Enterprises. Accordingly, the entire dues to vendors has been classified as payable to other than MSME. 6. The Company has filed application with NCLT for Merger of Golden Drugs Private Limited , a wholly owned subsidiary of the Company. 7. The Company has made the grant of 4,16,500 stock options during the year 2021-22 under 'Bal Pharma Ltd Employee Stock Option Scheme 2014' to its employees. These Stock options will vest in line with the Scheme. 8. Previous period figures have been regrouped/ reaaranged wherever considered necessary to conform to the period presentation. Single segment 2023-04-01 2024-03-31 Audited Standalone 3385399000.00 33520000.00 3418919000.00 1815709000.00 112272000.00 -10565000.00 561095000.00 152355000.00 84516000.00 582479000.00 3297861000.00 121058000.00 0.00 121058000.00 32023000.00 -13688000.00 18335000.00 0.00 102723000.00 0.00 0.00 0.00 0.00 102723000.00 3537000.00 106260000.00 0.00 0.00 158043000.00 10 0.00 6.72 6.75 0.00 0.00 6.72 6.75 Other Expenses 159361000.00 Other Expenses 582479000.00 531799000.00 4722000.00 0.00 113783000.00 95756000.00 0.00 26574000.00 122330000.00 28975000.00 801609000.00 874912000.00 67567000.00 1031034000.00 40371000.00 90965000.00 351151000.00 10212000.00 1591300000.00 345201000.00 2811413000.00 3613022000.00 158044000.00 897773000.00 1055817000.00 1055817000.00 363494000.00 363494000.00 49349000.00 39376000.00 13412000.00 465631000.00 974811000.00 898442000.00 92794000.00 1966047000.00 94035000.00 9316000.00 22176000.00 2091574000.00 2557205000.00 3613022000.00 152355000.00 101963000.00 0.00 -77743000.00 0.00 4638000.00 370000.00 0.00 0.00 -9300000.00 0.00 -15314000.00 0.00 84516000.00 0.00 3326000.00 0.00 13258000.00 -3852000.00 -10353000.00 0.00 -16087000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 259951000.00 381009000.00 0.00 0.00 0.00 45432000.00 -2083000.00 333494000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -104972000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6797000.00 0.00 -86114000.00 0.00 25655000.00 0.00 0.00 12181000.00 0.00 0.00 -7269000.00 0.00 0.00 85997000.00 0.00 0.00 0.00 15690000.00 -152355000.00 0.00 0.00 242112000.00 601261000.00 0.00 601261000.00 0.00 601261000.00